Fritextsökning
Artiklar per år
Innehållstyper
-
Anna Törner: ”Me Tarzan, you Jane, nä det funkar inte längre!”
”Kanske det är dags att sluta att prata om manliga och kvinnliga egenskaper och istället referera till människor som handlingskraftiga, analyserande, inlyssnande och strategiska? Helt utan referens till kromosomuppsättning?”, skriver Anna Törner i en krönika.
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thrombosis is an ongoing challenge. In the late 1980s, scientists at Maastricht University in the Netherlands developed an innovative method, the thrombin generation assay (TGA), which provides a complete overview of a physiological process crucial for maintaining normal haemostasis.
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.
-
Sanofi och Novavax i samarbete om kombinerat covid- och influensavaccin
Franska Sanofi har tecknat ett licensavtal om försäljning av Novavax covidvaccin och om utvecklingen av nya kombinationsvaccin mot influensa och covid-19. Uppgörelsen innebär också att Sanofi blir minoritetsägare i det amerikanska bolaget.
-
Ännu en stämning mot Pfizer om mRNA – GSK anklagar konkurrenten
Det brittiska läkemedelsföretaget GSK gör som Moderna och stämmer Pfizer och Biontech för mRNA-teknologi för covidvaccin.
-
Moderna utökar samarbete med Open AI – växlar upp med artificiell intelligens
AI-assistenter i alla delar av verksamheten. Det är målet för Moderna, som slutit ett nytt avtal med Open AI. Något som kommer öka kapaciteten kraftigt, enligt vd Stéphane Bancel.
-
Nocebo – the evil twin that makes you feel worse
The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala researcher Charlotte Blease, co-author of a book on the phenomenon.
-
Nocebo – den onda tvillingen som får dig att må sämre
Placeboeffekten är väl känd inom vården – men det gäller inte dess motsats: nocebo. "Det är en liten effekt, men den kan få stora återverkningar", säger Uppsalaforskaren Charlotte Blease, medförfattare till en bok om fenomenet.
-
Vertex betalar 52 miljarder för bolag inom autoimmuna sjukdomar
Amerikanska Vertex Pharmaceuticals köper biotechbolaget Alpine Immune Sciences för 4,9 miljarder dollar, motsvarande drygt 52 miljarder kronor.
-
Recipharm divests five Swedish plants
Swedish contract manufacturer Recipharm is selling its facilities in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development to US private equity company Blue Wolf Capital Partners.
-
The life science strategy – what the industry wants
The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s competitiveness, the accessibility of health data and the integration of innovation in healthcare are some of the points that are essential to review.
-
”We need compatibility“
Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on efficient and secure management of patient data and equal access to medicines.
-
Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”
It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or whether they are indeed right (or wrong) for the current project, Anna Törner writes in a column.
-
“What is important is to create an overview and understanding from different perspectives”
Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diagnostics of the Future event.
-
From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”
A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic region with vaccines during a future pandemic. These are some of the projects underway at NorthX Biologics – under the direction of new CEO Janet Hoogstraate.
-
Marie Gårdmark: ”Interchangeable biological medicines – soon in a pharmacy near you?”
”Generic competition is an effective way to push down drug prices, but it has not worked equally well for biosimilars. Biosimilars require more time to gain market share compared to generics, and new biosimilars do not always lead to lower prices” writes Marie Gårdmark in a column.
-
“Don’t postpone the transition to IVDR”
Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, Head of Unit at the Swedish Medical Products Agency, who continues to persistently spread her
-
KI’s new super machine measures brain activity in real-time – “A very expensive hairdo”
Using brand-new, super-advanced equipment, researchers at Karolinska Institutet can now measure brain activity in real-time, with higher resolution than previously possible. “This opens up fantastic opportunities”, says brain researcher Daniel Lundqvist.
-
Särläkemedelsbolag blir första hyresgästen i Fysiologen
Nu får den pånyttfödda byggnaden Fysiologen på Campus Solna sin första hyresgäst.
-
Byggstart för svenska innovationsklustret – fördubblar sin yta
Nu tas första spadtaget för Goco Active Lab, ett nytt nationellt center som ska stärka svensk life science.
-
Suing the company – for NOT developing a new HIV drug
Was Gilead putting a steady flow of profits from its cash cow ahead of developing a new and safer drug? According to a large number of US HIV patients in a legal case with an unusual twist, the answer is yes.
BREAKING